AzTrials
AzTrials

Hypertrophic CardiomyopathyNCT06368518

Austrian Hypertrophic Cardiomyopathy Registry

An observational study of Hypertrophic Cardiomyopathy, run by Medical University of Graz at 15 sites in Austria.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The Austrian Hypertrophic Cardiomyopathy (HCM) Registry is a prospective, multicenter registry enrolling patients at multiple outpatient clinics across Austria including academic and non-academic centers. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Hypertrophic Cardiomyopathy
How many people
1,000 participants
Where
15 sitesAustria
Study dates
8 Mar 2024to Mar 2044
How long will I take part?
20 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study population includes subjects who fulfill criteria of HCM and are treated in Austria.

Who may be able to join

  • Patients admitted to the HCM outpatient clinic of participating centers of the HCM Registry
  • Interventricular septal thickness ≥ 13 mm and cardiomyopathy-specific red flags OR Interventricular septal thickness ≥ 15 mm not explainable by loading conditions OR Interventricular septal thickness ≥ 17 mm
  • Willingness and ability to provide signed informed consent form (ICF) prior to participation in any study-related procedures

Who cannot join

  • Age < 18 years
  • Known cardiac amyloidosis

Trial locations and contacts

15 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Nicolas D Verheyen, MD contact

004331638530173

nicolas.verheyen@medunigraz.at

Viktoria Santner, MD contact

004331638531233

viktoria.santner@medunigraz.at

15 sites in 1 country

Austria15 sites, 14 recruiting

  • Hospital St. Josef Braunau

    Braunau am Inn, Upper Austria, 5280

    Johann Auer, MD, Johann.Auer@khbr.at

    Recruiting

  • Hospital Graz 2 West

    Graz, Styria, 8020

    Gert Waltl, MD, gert.waltl@kages.at

    Recruiting

  • Medical University of Graz

    Graz, Styria, 8036

    Nicolas D Verheyen, MD, 004331638530173, nicolas.verheyen@medunigraz.at

    Viktoria Santner, MD, viktoria.santner@medunigraz.at

    Recruiting

  • Medical University of Innsbruck

    Innsbruck, Tyrol, 6020

    Marc-Michael Zaruba, MD, marc-michael.zaruba@tirol-kliniken.at

    Recruiting

  • Kepler University Hospital Linz

    Linz, Linz, 4021

    Christian Reiter, MD, christian.reiter@kepleruniklinikum.at

    Recruiting

  • Ordensklinikum Linz

    Linz, Upper Austria, 4020

    Christian Ebner, MD, christian.ebner@ordensklinikum.at

    Recruiting

  • Paracelsus Medical University of Salzburg

    Salzburg, State of Salzburg, 5020

    Christina Granitz, MD, c.granitz@salk.at

    Recruiting

  • General Hospital St. Johann in Tirol

    Sankt Johann in Tirol, 6380

    Peter P Rainer, MD, peter.rainer@medunigraz.at

    Recruiting

  • University Hospital St. Pölten

    Sankt Pölten, Lower Austria, 3100

    Deddo Mörtl, MD, Deddo.Moertl@stpoelten.lknoe.at

    Recruiting

  • Clinic Cardinal Schwarzenberg

    Schwarzach im Pongau, State of Salzburg, 5620

    Anna Rab, MD, Anna.rab@icloud.com

    Recruiting

  • Medical University of Vienna

    Vienna, State of Vienna, 1090

    Daniel Dalos, MD, daniel.dalos@meduniwien.ac.at

    Recruiting

  • Favoriten Clinic Vienna

    Vienna, State of Vienna, 1100

    Active, not recruiting

  • Klinik Ottakring

    Vienna, State of Vienna

    Stephan Dobner, MD, stephandobner@me.com

    Recruiting

  • Clinic Wels-Grieskirchen

    Wels-Grieskirchen, 4600

    Thomas Weber, MD, thomas.weber3@liwest.at

    Recruiting

  • Hospital Landesklinikum Wiener Neustadt

    Wiener Neustadt, Lower Austria, 2700

    Martin Grübler, MD, martin.gruebler@gmx.net

    Recruiting

Other trials in Austria

About this study

The Austrian Hypertrophic Cardiomyopathy (HCM) Registry is a prospective, multicenter registry enrolling patients at multiple outpatient clinics across Austria including academic and non-academic centers. Patients will undergo a structured examination process including assessment for symptoms of HCM, past medical history, concomitant medication, family history and the presence of HCM-specific red flags. Furthermore, clinical data derived from electrocardiogram, echocardiography, laboratory analysis, and genetic testing will be collected focusing on a lean variable dictionary and, in addition, specific hypothesis-driven research parameters. All data are entered into an electronic case report form (eCRF) (Phoenix Clinical Trial Management System). In order to perform multicenter analyses, data can be extracted from the eCRF after approval by the steering committee.

Read the detailed description

The Austrian Hypertrophic Cardiomyopathy (HCM) Registry is a prospective, multicenter registry enrolling patients at multiple outpatient clinics across Austria including academic and non-academic centers. Patients will undergo a structured examination process including assessment for symptoms of HCM, past medical history, concomitant medication, family history and the presence of HCM-specific red flags. Furthermore, clinical data derived from electrocardiogram, echocardiography, laboratory analysis, and genetic testing will be collected focusing on a lean variable dictionary and, in addition, specific hypothesis-driven research parameters. All data are entered into an electronic case report form (eCRF) (Phoenix Clinical Trial Management System). Every site will nominate one representative for the steering committee which will serve as the regulatory authority with the compentence to approve research and funding proposals.

The Austrian multicenter HCM Registry aims to facilitate a wide range of innovative cross-sectional and longitudinal epidemiological analyses unravelling gaps in evidence in HCM. The standardized clinical assessment might harmonize standards of clinical care in HCM patients in Austria.

Keywords
Hypertrophic Cardiomyopathy, Left ventricular hypertrophy, Hypertrophic Phenotype
Medical subject headings
Cardiomyopathy, Hypertrophic, Hypertrophy, Left Ventricular

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. All cause mortality

    All cause mortality

    Measured: Through study completion, on average 20 years

  2. Cardiovascular events

    Cardiovascular events

    Measured: Through study completion, on average 20 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Apr 2024
  2. Study start8 Mar 2024
  3. Primary completionMar 2044 (estimated)
  4. Study completionMar 2044 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,000 participants (estimated)
Target duration
20 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT06368518
Sponsor's protocol ID
ID01/2024/MZHCM-Reg/NV
Status last verified
Nov 2025
First submitted
10 Apr 2024
Last updated
5 Dec 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Santner V, Granitz C, Grubler MR, Dalos D, Reiter C, Zaruba MM, Auer J, Moertl D, Rab A, Rainer PP, Waltl G, Ebner C, Weber T, Bonderman D, Dobner S, Tuppinger H, Holler V, Schwegel N, Ablasser K, Zirlik A, Graf A, Gharibeh S, Lanzerstorfer J, Worgotter K, Mann C, Masood S, Meledeth C, Steinwender C, Logtenberg A, Messner M, Primus C, Auersperg P, Mackova L, Baurecht C, Winkler S, Schneiderbauer-Porod S, Danninger K, Charwat-Resl S, Harbich P, Krenn R, Verheyen N. The prospective Austrian hypertrophic cardiomyopathy registry - design, methods and results of the run-in period. Heart Fail Rev. 2026 Apr 15;31(1):56. doi: 10.1007/s10741-026-10630-6.

    PubMed 41984359

Questions about this trial

What is this clinical trial studying?

An observational study of Hypertrophic Cardiomyopathy, run by Medical University of Graz at 15 sites in Austria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 5 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 15 sites in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Nicolas D Verheyen, MD (004331638530173, nicolas.verheyen@medunigraz.at), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

All cause mortality (time frame: Through study completion, on average 20 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06368518, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in